PPPallavi Pandey

Pallavi Pandey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pallavi Pandey has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Ankur Pandey

    From the Russell H. Morgan Department of Radiology and Radiological Sciences (P.P., A.P., Y.L., M.A.G., P.K., S.Z., I.R.K.) and the Departments of Medicine, Division of Gastroenterology and Hepatology (A.M.O.L., M.C., M.S.G.), Pathology (R.H.H., M.S.G.), and Surgery, Division of Surgical Oncology (C.W.), Johns Hopkins University School of Medicine, 600 N Wolfe St, Room 143, Baltimore, MD 21287

    11 shared publications
  • Ihab R. Kamel

    University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado

    11 shared publications
  • Farnaz Najmi Varzaneh

    Russell H. Morgan Department of Radiology and Radiological Sciences, Central Radiology, Johns Hopkins University School of Medicine, 600 N Wolfe St, Room 143, Baltimore, MD, 21287, USA

    7 shared publications
  • Pegah Khoshpouri

    Russell H. Morgan Department of Radiology and Radiological Sciences, Central Radiology, Johns Hopkins University School of Medicine, 600 N Wolfe St, Room 143, Baltimore, MD, 21287, USA

    7 shared publications
  • Manijeh Zarghampour

    From the Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, 600 N Wolfe St, Room 143, Baltimore, MD 21287

    6 shared publications
  • Mounes Aliyari Ghasabeh

    Russell H. Morgan Department of Radiology and Radiological Sciences, Central Radiology, Johns Hopkins University School of Medicine, 600 N Wolfe St, Room 143, Baltimore, MD, 21287, USA

    6 shared publications

Latest Publications

  • Follow-up of Incidentally Detected Pancreatic Cystic Neoplasms: Do Baseline MRI and CT Features Predict Cyst Growth?

    by Pallavi Pandey, Ankur Pandey, Yan Luo, Mounes Aliyari Ghasabeh, Pegah Khoshpouri, Sanaz Ameli, Anne Marie O’bRoin-Lennon, Marcia Canto, Ralph H. Hruban, Michael S. Goggins, et al.

    Pancreatic cystic neoplasms 15–25 mm in size were most likely to show growth on follow-up images obtained with CT or MRI; however, very small lesions (<5 mm) showed no interval growth until at leas... Background Incidental detection of pancreatic cystic neoplasm (PCN) has increased. Since a small percentage of PCNs possess malignant potential, management is challenging. The recently revised Amer...


  • Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization

    by Yan Luo, Sanaz Ameli, Ankur Pandey, Pegah Khoshpouri, Mounes Aliyari Ghasabeh, Pallavi Pandey, Zhen Li, Daoyu Hu, Ihab R. Kamel

    To evaluate the accuracy and reproducibility of semi-quantitative visual assessment of hepatic tumor burden (HTB) on MRI and to investigate its prognostic value in predicting overall survival (OS) in neuroendocrine liver metastases (NELMs) treated with transarterial chemoembolization (TACE).


  • Added value of apparent diffusion coefficient in distinguishing between serous and mucin-producing pancreatic cystic neoplasms

    by Pallavi Pandey, Ankur Pandey, Nannan Shao, Farnaz Najmi Varzaneh, Mounes Aliyari Ghasabeh, Manijeh Zharghampour, Pegah Khoshpouri, Daniel Fouladi, John Eng, Anne Marie O’broin-Lennon, et al.

    To evaluate the added value of diffusion-weighted imaging (DWI) on MRI in differentiating serous from mucin-producing pancreatic cystic neoplasms (PCNs).


  • Baseline Volumetric Multiparametric MRI: Can It Be Used to Predict Survival in Patients with Unresectable Intrahepatic Cholangiocarcinoma Undergoing Transcatheter Arterial Chemoembolization?

    by Ankur Pandey, Pallavi Pandey, Mounes Aliyari Ghasabeh, Manijeh Zarghampour, Pegah Khoshpouri, Sanaz Ameli, Yan Luo, Ihab R. Kamel

    Baseline multiparametric MRI assessment including volumetric apparent diffusion coefficient, percentage viable tumor volume, and viable tumor burden can help predict mortality risk in patients with unresectable intrahepatic cholangiocarcinoma undergoing transcatheter arterial chemoembolization. PurposeTo evaluate whether baseline MRI can help predict survival in patients with unresectable intrahepatic cholangiocarcinoma (ICCA) undergoing transcatheter arterial chemoembolization (TACE).Materials and MethodsThis retrospective study was compliant with HIPAA and approved by the institutional review board. The requirement to obtain informed consent was waived. The study included 111 patients (mean age, 62 years ± 12; range, 29–86 years), with 44 men (mean age, 61 years ± 12; range, 29–81 years) and 67 women (mean age, 63 years ± 12; range, 34–86 years). Patients underwent TACE after baseline MRI, which included contrast-enhanced and diffusion-weighted imaging with apparent diffusion coefficient (ADC) mapping between 2003 and 2016. The single largest tumor was assessed independently by a radiologist for anatomic and functional (viable tumor volume, percentage viable tumor volume [100 × viable tumor volume/whole tumor volume], viable tumor burden [100 × viable tumor volume/whole liver volume], and ADC)...


  • Correlation between quantitative liver and spleen volumes and disease severity in primary sclerosing cholangitis as determined by Mayo risk score

    by Pegah Khoshpouri, Sanaz Ameli, Mounes Aliyari Ghasabeh, Ankur Pandey, Manijeh Zarghampour, Farnaz Najmi Varzaneh, Angela Jacob, Pallavi Pandey, Yan Luo, Ihab R. Kamel


  • Long-term follow-up of hepatic adenoma and adenomatosis: analysis of size change on imaging with histopathological correlation

    by N. Shao, A. Pandey, M.A. Ghasabeh, P. Khoshpouri, P. Pandey, F.N. Varzaneh, M. Zarghampour, D. Fouladi, T.M. Pawlik, R.A. Anders, et al.


  • Unresectable Intrahepatic Cholangiocarcinoma: Multiparametric MR Imaging to Predict Patient Survival

    by Ankur Pandey, Pallavi Pandey, Mounes Aliyari Ghasabeh, Farnaz Najmi Varzaneh, Nannan Shao, Pegah Khoshpouri, Manijeh Zarghampour, Daniel Fadaei Fouladi, Robert Liddell, Ihab R. Kamel

    Purpose: To determine the performance of magnetic resonance (MR) imaging-based tumor metrics for evaluation of response to transarterial chemoembolization (TACE) in patients with unresectable intrahepatic cholangiocarcinoma (ICCA). Materials and Methods: Ninety-four patients with unresectable ICCA underwent baseline and follow-up MR imaging after TACE and were followed up until death or end of study duration. Lesions were analyzed for anatomic (Response Evaluation Criteria in Solid Tumors [RECIST] and tumor volume) and functional (viable tumor volume, viable tumor burden, and apparent diffusion coefficient [ADC]) volumetric MR parameters by using semiautomatic software. Response was assessed by using changes in viable tumor volume by using modified RECIST (mRECIST)-derived thresholds (three-dimensional mRECIST), viable tumor burden, and ADC. Overall survival was the primary endpoint. Cox-regression and Kaplan-Meier survival analysis were used. Results: Tumor volume did not change after TACE (P=.07) whereas RECIST diameter showed a small change (22.6%; P=.02). There was an increase in ADC (20.7%) and a decrease in viable tumor volume (229.3%) and viable tumor burden (229.1%; P<.001 for all). Higher overall survival was noted among responders by using thresholds of 25% increase in ADC, 66% decrease in viable tumor volume, and 50% decrease in viable tumor burden (log-rank test, P<.05). Hazard ratio for nonresponders by using ADC, three-dimensional mRECIST, and viable tumor burden at multivariable analysis was 2.9 (P=.004), 4.1 (P =.009), and 4.0 (P=.002), respectively. Survival differences were noted for patients who showed response by using all three parameters (ADC, three-dimensional mRECIST, and viable tumor burden) versus those who showed response by using either one or two of these parameters versus those who showed no response (P<.001). Conclusion: Changes in volumetric ADC, viable tumor volume, and viable tumor burden at MR imaging provide prognostic information among patients with unresectable ICCA who undergo TACE. (c) RSNA, 2018


  • Utility of volumetric contrast‐enhanced and diffusion‐weighted MRI in differentiating between common primary hypervascular liver tumors

    by Manijeh Zarghampour, Daniel F. Fouladi, Ankur Pandey, Mounes Aliyari Ghasabeh, Pallavi Pandey, Farnaz Najmi Varzaneh, Pegah Khoshpouri, Nannan Shao, Li Pan, Robert Grimm, et al.

    Background: Differentiating between hepatocellular carcinoma (HCC), focal nodular hyperplasia (FNH), and hepatocellular adenoma (HCA) is usually achievable by MRI. However, in some cases with atypical imaging findings accurate diagnosis may be difficult.Purpose: To assess the diagnostic value of volumetric contrast‐enhanced (CE) and volumetric diffusion‐weighted imaging (DWI) in differentiating between HCC, FNH, and HCA.Study Type: Retrospective.Subjects: In all, 143 patients (206 lesions): 42 HCA (81 lesions), 51 FNH (65 lesions), and 50 HCC (60 lesions).Field Strength/sequence: 1.5T MRI, T1‐T2WI, DWI.Assessment: Patients underwent CE‐MRI and DWI (b = 0, 750 mm2/s). Volumetric assessment of lesions' contrast enhancement and apparent diffusion coefficient (ADC) was performed with semiautomatic software after 3D image registration and segmentation by an observer and compared between three lesion groups. The diagnosis of lesions was based on histopathology, typical MRI findings, and/or follow‐up.Statistical Tests: Independent t‐test was used to compare parameters between two groups, one‐way analysis of variance (ANOVA) between three groups, and receiver operator characteristic curve (ROC) analysis to define under‐curve area and optimal cutoff.Results: Mean values (±standard deviation) for HCC, FNH, and HCA, respectively, were: 1) arterial enhancement (%), 40.5 ± 13.2, 88.6 ± 32.6, 69.6 ± 25.1; 2) venous enhancement (%) 72.4 ± 22.1, 95.2 ± 30.9, 80.7 ± 30.6; and 3) ADC (10−6 mm2/s) 1404.5 ± 168.1, 1413.4 ± 232.1, 1070.1 ± 232.1. ADC was the best differentiator of HCA from FNH (at 1211 × 10−6 mm2/s; sensitivity 80.4%, specificity 71.7%) and arterial enhancement was the best differentiator of HCC from both HCA (at 48%; sensitivity 80.0%, specificity 80.5%) and FNH (at 52%; sensitivity 85.7%, specificity 85.4%). A combination of arterial enhancement and ADC (at 50% and 1227 × 10−6 mm2/s) differentiated three types of tumors with high specificity (87.9%).Data Conclusion: Volumetric CE‐MRI and volumetric DWI can help to differentiate between HCC, FNH, and HCA.Level of Evidence: 1Technical Efficacy: Stage 2J. Magn. Reson. Imaging 2018;48:1080–1090.


  • Are pancreatic IPMN volumes measured on MRI images more reproducible than diameters? An assessment in a large single-institution cohort

    by Pallavi Pandey, Ankur Pandey, Farnaz Najmi Varzaneh, Mounes Aliyari Ghasabeh, Daniel Fouladi, Pegah Khoshpouri, Nannan Shao, Manijeh Zarghampour, Ralph H. Hruban, Marcia Canto, et al.

    To assess reproducibility of volume and diameter measurement of intraductal papillary mucinous neoplasms (IPMNs) on MRI images.


  • Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation

    by Farnaz Najmi Varzaneh, Ankur Pandey, Mounes Aliyari Ghasabeh, Nannan Shao, Pegah Khoshpouri, Pallavi Pandey, Manijeh Zarghampour, Daniel Fouladi, Robert Liddell, Robert Albert Anders, et al.

    Objective To investigate whether volumetric enhancement on baseline MRI and volumetric oil deposition on unenhanced CT would predict HCC necrosis and response post-TACE. Method Of 115 retrospective HCC patients (173 lesions) who underwent cTACE, a subset of 53 HCC patients underwent liver transplant (LT). Semiautomatic volumetric segmentation of target lesions was performed on dual imaging to assess the accuracy of predicting tumour necrosis after TACE in the whole cohort and at pathology in the LT group. Predicted percentage tumour necrosis is defined as 100 % - (%baseline MRI enhancement - %CT oil deposition). Results Mean predicted tumour necrosis by dual imaging modalities was 61.5 % ± 31.6%; mean percentage tumour necrosis on follow-up MRI was 63.8 % ± 31.5 %. In the LT group, mean predicted tumour necrosis by dual imaging modalities was 77.6 % ± 27.2 %; mean percentage necrosis at pathology was 78.7 % ± 31.5 %. There was a strong significant correlation between predicted tumour necrosis and volumetric necrosis on MRI follow-up (r = 0.889, pp• Imaging-based tumour response can assist in therapeutic decisions. • Lipiodol retention as carrier agent in cTACE is a tumour necrosis biomarker. • Predicting tumour necrosis with dual imaging potentially obviates immediate post-treatment MRI. • Predicting tumour necrosis would facilitate further therapeutic decisions in HCC post-cTACE. • Pre-TACE MRI and post-TACE CT predict necrosis in treated HCC.